These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33824764)

  • 21. Characterization of an extemporaneous liquid formulation of lisinopril.
    Thompson KC; Zhao Z; Mazakas JM; Beasley CA; Reed RA; Moser CL
    Am J Health Syst Pharm; 2003 Jan; 60(1):69-74. PubMed ID: 12533979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioavailability of an extemporaneous suspension of propafenone made from tablets.
    Olguín HJ; Pérez CF; Pérez JF; Mendiola BR; Portugal MC; Chávez JB
    Biopharm Drug Dispos; 2006 Jul; 27(5):241-5. PubMed ID: 16586461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.
    Sae Yoon A; Sawatdee S; Woradechakul C; Sae Chee K; Atipairin A
    Sci Pharm; 2015; 83(4):659-70. PubMed ID: 26839846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiway analysis methods applied to the fluorescence excitation-emission dataset for the simultaneous quantification of valsartan and amlodipine in tablets.
    Dinç E; Ertekin ZC; Büker E
    Spectrochim Acta A Mol Biomol Spectrosc; 2017 Sep; 184():255-261. PubMed ID: 28514719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extemporaneous suspension of propafenone: attending lack of pediatric formulations in Mexico.
    Juárez Olguín H; Flores Pérez C; Ramírez Mendiola B; Coria Jiménez R; Sandoval Ramírez E; Flores Pérez J
    Pediatr Cardiol; 2008 Nov; 29(6):1077-81. PubMed ID: 18587605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Drug Content, Stability Analysis, and Qualitative Assessment of Pharmacists' Opinions of Two Exemplar Extemporaneous Formulations.
    Kirkby M; Moffatt K; Rogers AM; McCague PJ; McElnay JC; Quinn C; McCullough LA; Barry J; Donnelly RF
    Molecules; 2020 Jul; 25(13):. PubMed ID: 32640709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High performance liquid chromatographic assay of amlodipine, valsartan and hydrochlorothiazide simultaneously and its application to pharmaceuticals, urine and plasma analysis.
    Shaikh JSA; Raut S; Abdul A; Pathan MAAK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Oct; 1155():122295. PubMed ID: 32771968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding.
    Rush SD; Vernak C; Zhao F
    Int J Pharm Compd; 2017; 21(1):83-87. PubMed ID: 28346201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does GastroPlus Support Similarity and Dissimilarity Factors of in vitro-in vivo Prediction in Biowaiver Studies? A Lower Strength Amlodipine As a Model Drug.
    Zaid AN; Shraim N; Radwan A; Jaradat N; Hirzallah S; Issa I; Khraim A
    Drug Res (Stuttg); 2018 Nov; 68(11):625-630. PubMed ID: 29791921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®.
    Honório Tda S; Pinto EC; Rocha HV; Esteves VS; dos Santos TC; Castro HC; Rodrigues CR; de Sousa VP; Cabral LM
    AAPS PharmSciTech; 2013 Sep; 14(3):1244-54. PubMed ID: 23943401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs Exforge: a randomized crossover study of healthy male volunteers.
    Choi HY; Kim YH; Kim MJ; Noh YH; Lee SH; Bae KS; Lim HS
    Am J Cardiovasc Drugs; 2014 Feb; 14(1):63-72. PubMed ID: 24174172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of extemporaneous oral itraconazole suspensions by dissolution profiles mapping.
    Tong HH; Chan H; Du Z; Zheng Y
    Int J Pharm Compd; 2010; 14(4):342-5. PubMed ID: 23965542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formulation and bioequivalence of two Valsartan/Amlodipine immediate release tablets after a single oral administration.
    Zaid AN; Natur S; Qaddomi A; Abualhasan M; Al-Ramahi R; Shraim N; Khammash S; Jaradat N
    Pak J Pharm Sci; 2014 Jul; 27(4):755-62. PubMed ID: 25015436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach.
    Komasaka T; Dressman J
    Eur J Pharm Sci; 2021 Feb; 157():105630. PubMed ID: 33122010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of allopurinol suspension compounded from tablets.
    Alexander KS; Davar N; Parker GA
    Int J Pharm Compd; 1997; 1(2):128-31. PubMed ID: 23995972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization.
    Ibrahim HK; El-Setouhy DA
    AAPS PharmSciTech; 2010 Mar; 11(1):189-96. PubMed ID: 20112137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of plasma concentrations using in silico modelling and simulation approach: Case of Acebutolol.
    Bokri E; Felfel H; Bahri S
    Ann Pharm Fr; 2021 Sep; 79(5):530-538. PubMed ID: 33675740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and Safety Profiles of a Fixed-Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3-Period Replicate Crossover Study.
    Kim S; Ko JW; Kim JR
    Clin Pharmacol Drug Dev; 2020 Apr; 9(3):386-394. PubMed ID: 31373174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.